Supplements & Nutritional Interventions

Purpose

Scope

Requirements

• Legal availability ≠ professional appropriateness ≠ individual safety. Legal or commercial availability of a product must not by itself be treated as evidence of individual appropriateness, efficacy or safety.
• Professionals must distinguish general supplement education, individualized recommendation and medical or therapeutic assessment, and act within their actual Scope of Practice.
• A recommendation intended to support general nutrient intake is not automatically equivalent to a therapeutic intervention intended to treat a disease or diagnosed deficiency. Therapeutic intent may trigger additional qualification, scope or legal requirements.
• Before making an individualized recommendation, factors relevant to the Professional's role should be considered, including purpose, person, product, dose, duration, combinations and known risk factors.
• The evidentiary basis of a claim must match the product actually used and the specific application. Formulation, Dose, Route, Population and Outcome should be considered when transferring evidence.
• Same ingredient does not automatically mean same evidence. Same label category does not mean same product evidence. Evidence relating to a single ingredient must not automatically be transferred to a finished product, different formulation, dose, route of administration or combination.
• Proprietary blends or incompletely transparent formulations must not be treated as equivalent to a studied formulation where composition or relevant doses cannot be adequately determined.
• Product substitution, brand changes or reformulation may change the evidence and safety assessment. Evidence and safety belong to the actual formulation used, not to the product category in general.
• Dose is part of both safety and evidence assessment. More is not automatically better. A higher dose must not be presented as more appropriate solely because a stronger effect is expected.
• Combinations must be assessed together. Assess the stack, not only the parts. Multiple supplements, medications, stimulants, fasting, alcohol, exercise, heat, cold or other stressors may create a different risk profile from any component alone.
• Total exposure to an ingredient or nutrient should be considered across multiple products and sources where relevant to risk or appropriateness. Assess total exposure across products, not only the dose printed on one label.
• Potential medication-supplement, supplement-supplement and relevant food-supplement interactions must be considered within professional competence. Where reliable individualized assessment is outside scope, specialist evaluation or referral is required.
• Relevant contraindications and higher-risk situations must be considered to the extent supported by professional competence. Depending on the intervention and context, these may include pregnancy, breastfeeding, age, medical conditions, planned procedures or changes in medication use; H-04 does not constitute a universal contraindication list.
• Previous tolerance of a supplement does not prove future safety when dose, formulation, combinations, health status or medication use changes.
• Product quality must not be inferred solely from branding, price, testimonials or marketing. Where quality is relevant to a professional recommendation, traceable information concerning identity, composition, source, manufacturing, storage, shelf life or appropriate independent testing should be considered where available and relevant.
• Quality claims should be traceable to what was actually tested – for example identity, purity, strength, composition, contaminants, batch, test method or testing body – where those details are relevant to the claim. A quality claim should be traceable to what was actually tested.
• Third-party testing may support information about product quality but does not automatically establish clinical efficacy, individual suitability or comprehensive safety. Its relevance and limitations depend on what was tested, when, how and for which batch. Third-party testing ≠ clinical efficacy or individual suitability.
• Label claims and manufacturer information may be information sources but do not replace independent evaluation of the evidence supporting an objective health claim.
• Health claims must comply with H-01 Health Information & Claims and U-03 Evidence & Scientific Communication. Scientific support does not automatically establish that a claim is legally permitted for the relevant product, professional role or jurisdiction.
• Supplements must not automatically be represented as safer or more appropriate because they are described as “natural,” “naturally derived,” “clean” or similar terms. Natural origin does not automatically determine dose, interaction risk, contamination risk or individual suitability.
• For new, experimental or insufficiently validated supplement interventions, evidence gaps and uncertainty must be communicated transparently. Experimental does not mean ineffective. It means not yet sufficiently established.
• Professionals must take relevant adverse reactions, new symptoms or substantial changes following an intervention seriously and respond appropriately within scope. Temporal association does not automatically prove causation. Documenting an event and determining its cause are separate tasks. Documenting an adverse event ≠ proving causality.
• For potentially relevant adverse events, Professionals must consider whether Stop, Modify, Refer or other appropriate action is required. Where red flags or possible acute danger are present, IHPSO Referral Levels and local emergency procedures apply.
• Documentation, reporting or regulatory duties relating to adverse events may vary by product, role and jurisdiction and must be assessed separately. H-04 does not create a universal reporting obligation.
• Where biomarkers or laboratory data are used to justify, select or monitor a supplement intervention, H-02 Biomarkers & Laboratory Data also applies.
• Where consumer wearables or consumer CGM are used to select or assess a supplement intervention, H-03 Wearables & Consumer Health Technology also applies.
• Where an IHPSO Evidence Classification is used, it must apply to a specific Product, Ingredient, Dose or Outcome claim and must not be assigned broadly to a supplement or product category.